Blood Cancer Therapeutics: Global Markets to 2023
Report Scope
This report organizes information from diverse sources into a comprehensive report that includes an overview, market dynamics, disease type, leading blockbuster drug profiles, regulations, reimbursement and patents. It analyzes prevailing blood cancer treatment guidelines in different geographic regions. The scope of the blood cancer therapeutic market is restricted to three disease areas: leukemia, lymphoma and multiple myeloma. Leukemia is classified into four sub-segments: chronic myeloid leukemia (CML), acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). This report includes an overview of the global market scenario for blood cancer treatments with base year data from 2017, estimations for 2018 and forecasts for 2019 to 2023, using CAGR projections. Market data in value terms is provided at global, regional and country levels for disease areas. This report forecasts the global market by disease area and discusses market data for leukemia, lymphoma and myeloma. This report involves regional market overviews for North America, Europe, Asia-Pacific and Rest of the World. Regional overviews provide information on the epidemiology of blood cancer by country and region and detailed market data for each region.
Market dynamics, such as trends and challenges, are discussed in the report. Global market drivers, trends and challenges influencing the blood cancer therapeutic market are also captured in this report. Detailed analyses of competitive environments, blockbuster drugs, pipelines, patents, the regulatory landscape and the reimbursement landscape are included in the report. The regulatory scenario is discussed for the United States, Europe and Japan to provide an overview of regulations for new drug launches. The reimbursement scenario is outlined for the United States and Europe to provide an overview to readers. The pipeline analysis chapter discusses four major disease areas to provide details about major pipeline developments. The competitive landscape discusses major manufacturers involved in the blood cancer therapeutic market, key developments and product offerings.
Report Includes:
This report organizes information from diverse sources into a comprehensive report that includes an overview, market dynamics, disease type, leading blockbuster drug profiles, regulations, reimbursement and patents. It analyzes prevailing blood cancer treatment guidelines in different geographic regions. The scope of the blood cancer therapeutic market is restricted to three disease areas: leukemia, lymphoma and multiple myeloma. Leukemia is classified into four sub-segments: chronic myeloid leukemia (CML), acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). This report includes an overview of the global market scenario for blood cancer treatments with base year data from 2017, estimations for 2018 and forecasts for 2019 to 2023, using CAGR projections. Market data in value terms is provided at global, regional and country levels for disease areas. This report forecasts the global market by disease area and discusses market data for leukemia, lymphoma and myeloma. This report involves regional market overviews for North America, Europe, Asia-Pacific and Rest of the World. Regional overviews provide information on the epidemiology of blood cancer by country and region and detailed market data for each region.
Market dynamics, such as trends and challenges, are discussed in the report. Global market drivers, trends and challenges influencing the blood cancer therapeutic market are also captured in this report. Detailed analyses of competitive environments, blockbuster drugs, pipelines, patents, the regulatory landscape and the reimbursement landscape are included in the report. The regulatory scenario is discussed for the United States, Europe and Japan to provide an overview of regulations for new drug launches. The reimbursement scenario is outlined for the United States and Europe to provide an overview to readers. The pipeline analysis chapter discusses four major disease areas to provide details about major pipeline developments. The competitive landscape discusses major manufacturers involved in the blood cancer therapeutic market, key developments and product offerings.
Report Includes:
- 41 data tables and 48 additional tables
- An overview of the global blood cancer therapeutics markets within the industry
- Analyses of global market trends with data from 2017 and 2018, and projections of compound annual growth rates (CAGRs) through 2023
- Regional dynamics of the market covering North America, Europe, Asia-Pacific and other emerging economies
- Discussion of major drivers, trends and challenges influencing blood cancer therapeutics market
- Information on the competitive environments, blockbuster drugs, pipeline analysis, patent analysis, and regulatory and reimbursement structure
- Coverage of regulatory environments for the United States, Europe and Japan; and information pertaining to the regulations for new drug launches
- A look at the reimbursement scenario outlined for the United States and Europe, and Pipeline analysis encompassing major disease area
- Examination of the competitive landscape and description of the major manufacturers involved in the blood cancer therapeutics market, key developments and product offerings
- Company profiles of leading market players, including AbbVie Inc., AstraZeneca plc, Bristol-Myers Squibb Co., GlaxoSmithKline plc, F. Hofmann-La Roche Ltd., and Novartis AG
CHAPTER 1 INTRODUCTION
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources
Methodology
Geographic Breakdown
Analyst's Credentials
BCC Custom Research
Related BCC Research Reports
CHAPTER 2 SUMMARY AND HIGHLIGHTS
CHAPTER 3 MARKET OVERVIEW
Market Definitions and Overview
Risk Factors
Symptoms
Diagnosis
Treatment and Therapy
Blood Cancer Timeline (Milestones in Research)
Product Approvals
Screening and Prevention Programs
Blood Cancer Awareness Month
The Heroes Among Us Campaign
Spot Leukemia Campaign
Make Blood Cancer Visible Campaign
CHAPTER 4 MARKET DYNAMICS AND TECHNOLOGY BACKGROUND
Market Drivers
Rising Incidence of Blood Cancer
Highly Sensitive Tests to Detect Minimal Residual Disease
Rising Government and Private Funding for Cancer Treatment
Challenges
Absence of Screening Programs for Early Detection
Low Awareness
CHAPTER 5 MARKET BREAKDOWN BY DISEASE TYPE
Leukemia
Lymphocytic Leukemias
Myelogenous Leukemias
Symptoms
Causes
Diagnosis
Treatment
Stages
Treatment and Therapies
Market Size and Analysis
Acute Lymphoblastic Leukemia (ALL)
Market Size and Analysis
Acute Myeloid Leukemia (AML)
Treatment and Therapies
Market Size and Analysis
Chronic Myeloid Leukemia (CML)
Market Size and Analysis
Chronic Lymphocytic Leukemia (CLL)
First-Line Treatment Regimen
Second-Line Treatment Regimen
Market Size and Analysis
Childhood Leukemia
Non-Hodgkin Lymphoma
Causes and Risk Factors
Signs and Symptoms
Diagnosis
Staging
Treatment
Non-Hodgkin Lymphoma Treatment for Children, Adolescents and Young Adults
Hodgkin Lymphoma
Causes and Risk Factors
Signs and Symptoms
Diagnosis
Staging
Treatment
Hodgkin Lymphoma Treatment for Children and Young Adults
Lymphoma Therapeutics: Market Size and Analysis
Multiple Myeloma
Symptoms
Causes and Risk Factors
Treatment and Therapies
Market Size and Analysis
Hairy Cell Leukemia (HCL)
Immunotherapy
CHAPTER 6 BLOOD CANCER TREATMENT REGIMENS
Targeted Therapy
B-Cell Leukemia/Lymphoma-2 (BCL-2) Inhibitors
FLT3 Inhibitors
Kinase Inhibitors
IDH Inhibitors
Proteasome Inhibitors
Immunotherapy
Monoclonal Antibodies (mAb) Therapy
Chemotherapy
DNA-Damaging Agents or Alkylating Agents
Antitumor Antibiotics
Antimetabolites
DNA-Repair Enzyme Inhibitors
Topoisomerase Inhibitors
Drug Combination Therapies
Leukemia
Non-Hodgkin Lymphoma
CAR-T Therapy
CHAPTER 7 MARKET BREAKDOWN BY REGION
North American Blood Cancer Therapeutic Market
Epidemiology
Market Size and Analysis
European Blood Cancer Therapeutic Market
Epidemiology
Market Size and Analysis
Asia-Pacific Blood Cancer Therapeutic Market
Epidemiology
Market Size and Analysis
Rest of the World Blood Cancer Therapeutic Market
Epidemiology
Market Size and Analysis
CHAPTER 8 PIPELINE ANALYSIS
Research and Development Overview
Blood Cancer Drugs Under Development
Promising Pipeline Molecules
Venclexta (AbbVie Inc.)
Empliciti (Bristol-Myers Squibb Co.)
Aplidin (PharmaMar)
SRF231 (Surface Oncology)
CHAPTER 9 REGULATORY AND REIMBURSEMENT STRUCTURE
Overview of Regulations
United States
Canada
Europe
Japan
China
Overview of Pricing and Reimbursement
United States
Europe
Japan
CHAPTER 10 COMPETITIVE LANDSCAPE AND KEY DEVELOPMENTS
Market Structure Analysis
Patent Expiration for Blockbuster Drugs
Key Industry Developments
CHAPTER 11 COMPANY PROFILES
ABBVIE INC.
Company Overview
Product Information
Development and Strategies
Financials
AMGEN INC.
Product Information
ASTRAZENECA PLC
Company Overview
Product Information
Financials
BOEHRINGER INGELHEIM PHARMACEUTICALS INC.
Company Overview
Financials
Development and Strategies
BRISTOL-MYERS SQUIBB CO.
Company Overview
Product Information
Financials
CELGENE CORP.
Company Overview
Product Information
Financials
GILEAD SCIENCES INC.
Company Overview
Financials
GLAXOSMITHKLINE PLC
Company Overview
Development and Strategies
Financials
F. HOFFMANN-LA ROCHE LTD.
Company Overview
Product Information
Financials
JANSSEN GLOBAL SERVICES LLC
Company Overview
Financials
MERCK & CO., INC.
Company Overview
Product Information
Financials
NOVARTIS AG
Company Overview
Product Information
Financials
PFIZER INC.
Company Overview
Product Information
Financials
TEVA PHARMACEUTICAL INDUSTRIES LTD.
Company Overview
Product Information
Development and Strategies
Financials
CHAPTER 12 APPENDIX: ACRONYMS AND GLOSSARY
Acronyms
Glossary of Terms
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources
Methodology
Geographic Breakdown
Analyst's Credentials
BCC Custom Research
Related BCC Research Reports
CHAPTER 2 SUMMARY AND HIGHLIGHTS
CHAPTER 3 MARKET OVERVIEW
Market Definitions and Overview
Risk Factors
Symptoms
Diagnosis
Treatment and Therapy
Blood Cancer Timeline (Milestones in Research)
Product Approvals
Screening and Prevention Programs
Blood Cancer Awareness Month
The Heroes Among Us Campaign
Spot Leukemia Campaign
Make Blood Cancer Visible Campaign
CHAPTER 4 MARKET DYNAMICS AND TECHNOLOGY BACKGROUND
Market Drivers
Rising Incidence of Blood Cancer
Highly Sensitive Tests to Detect Minimal Residual Disease
Rising Government and Private Funding for Cancer Treatment
Challenges
Absence of Screening Programs for Early Detection
Low Awareness
CHAPTER 5 MARKET BREAKDOWN BY DISEASE TYPE
Leukemia
Lymphocytic Leukemias
Myelogenous Leukemias
Symptoms
Causes
Diagnosis
Treatment
Stages
Treatment and Therapies
Market Size and Analysis
Acute Lymphoblastic Leukemia (ALL)
Market Size and Analysis
Acute Myeloid Leukemia (AML)
Treatment and Therapies
Market Size and Analysis
Chronic Myeloid Leukemia (CML)
Market Size and Analysis
Chronic Lymphocytic Leukemia (CLL)
First-Line Treatment Regimen
Second-Line Treatment Regimen
Market Size and Analysis
Childhood Leukemia
Non-Hodgkin Lymphoma
Causes and Risk Factors
Signs and Symptoms
Diagnosis
Staging
Treatment
Non-Hodgkin Lymphoma Treatment for Children, Adolescents and Young Adults
Hodgkin Lymphoma
Causes and Risk Factors
Signs and Symptoms
Diagnosis
Staging
Treatment
Hodgkin Lymphoma Treatment for Children and Young Adults
Lymphoma Therapeutics: Market Size and Analysis
Multiple Myeloma
Symptoms
Causes and Risk Factors
Treatment and Therapies
Market Size and Analysis
Hairy Cell Leukemia (HCL)
Immunotherapy
CHAPTER 6 BLOOD CANCER TREATMENT REGIMENS
Targeted Therapy
B-Cell Leukemia/Lymphoma-2 (BCL-2) Inhibitors
FLT3 Inhibitors
Kinase Inhibitors
IDH Inhibitors
Proteasome Inhibitors
Immunotherapy
Monoclonal Antibodies (mAb) Therapy
Chemotherapy
DNA-Damaging Agents or Alkylating Agents
Antitumor Antibiotics
Antimetabolites
DNA-Repair Enzyme Inhibitors
Topoisomerase Inhibitors
Drug Combination Therapies
Leukemia
Non-Hodgkin Lymphoma
CAR-T Therapy
CHAPTER 7 MARKET BREAKDOWN BY REGION
North American Blood Cancer Therapeutic Market
Epidemiology
Market Size and Analysis
European Blood Cancer Therapeutic Market
Epidemiology
Market Size and Analysis
Asia-Pacific Blood Cancer Therapeutic Market
Epidemiology
Market Size and Analysis
Rest of the World Blood Cancer Therapeutic Market
Epidemiology
Market Size and Analysis
CHAPTER 8 PIPELINE ANALYSIS
Research and Development Overview
Blood Cancer Drugs Under Development
Promising Pipeline Molecules
Venclexta (AbbVie Inc.)
Empliciti (Bristol-Myers Squibb Co.)
Aplidin (PharmaMar)
SRF231 (Surface Oncology)
CHAPTER 9 REGULATORY AND REIMBURSEMENT STRUCTURE
Overview of Regulations
United States
Canada
Europe
Japan
China
Overview of Pricing and Reimbursement
United States
Europe
Japan
CHAPTER 10 COMPETITIVE LANDSCAPE AND KEY DEVELOPMENTS
Market Structure Analysis
Patent Expiration for Blockbuster Drugs
Key Industry Developments
CHAPTER 11 COMPANY PROFILES
ABBVIE INC.
Company Overview
Product Information
Development and Strategies
Financials
AMGEN INC.
Product Information
ASTRAZENECA PLC
Company Overview
Product Information
Financials
BOEHRINGER INGELHEIM PHARMACEUTICALS INC.
Company Overview
Financials
Development and Strategies
BRISTOL-MYERS SQUIBB CO.
Company Overview
Product Information
Financials
CELGENE CORP.
Company Overview
Product Information
Financials
GILEAD SCIENCES INC.
Company Overview
Financials
GLAXOSMITHKLINE PLC
Company Overview
Development and Strategies
Financials
F. HOFFMANN-LA ROCHE LTD.
Company Overview
Product Information
Financials
JANSSEN GLOBAL SERVICES LLC
Company Overview
Financials
MERCK & CO., INC.
Company Overview
Product Information
Financials
NOVARTIS AG
Company Overview
Product Information
Financials
PFIZER INC.
Company Overview
Product Information
Financials
TEVA PHARMACEUTICAL INDUSTRIES LTD.
Company Overview
Product Information
Development and Strategies
Financials
CHAPTER 12 APPENDIX: ACRONYMS AND GLOSSARY
Acronyms
Glossary of Terms
LIST OF TABLES
Summary Table: Global Market for Blood Cancer Therapeutics, by Disease Type, Through 2023
Table 1: Type of Blood Cancers (Hematological Cancer)
Table 2: Milestones in the History of Leukemia
Table 3: Product Approvals, 2016-2018
Table 4: Classification of Leukemia
Table 5: Types of Leukemia, Key Features, Occurrence
Table 6: Diagnostic Examination for Leukemia
Table 7: PCR Tests
Table 8: Additional Tests
Table 9: Treatments for Leukemia
Table 10: Newer Classes of Drugs
Table 11: Types of Stem Cell Transplantation
Table 12: Types of Targeted Therapies
Table 13: Types of Radiation Therapies
Table 14: Global Market for Leukemia Therapeutics, by Subtype, Through 2023
Table 15: Global Market for Leukemia Therapeutics, by Region, Through 2023
Table 16: Acute Lymphoblastic Leukemia (ALL) Treatment
Table 17: Therapies Approved for Acute Lymphoblastic Leukemia (ALL)
Table 18: Global Market for Acute Lymphocytic Leukemia (ALL) Therapeutics, by Region, Through 2023
Table 19: Therapies Approved for Acute Myeloid Leukemia
Table 20: Global Market for Acute Myeloid Leukemia Therapeutics, by Region, Through 2023
Table 21: Therapies Approved for Chronic Myeloid Leukemia
Table 22: Global Market for Chronic Myeloid Leukemia Therapeutics, by Region, Through 2023
Table 23: Therapies Approved for Chronic Lymphocytic Leukemia
Table 24: Global Market for Chronic Lymphocytic Leukemia Therapeutics, by Region, Through 2023
Table 25: Childhood Leukemia, Five-Year Relative Survival, Age 0-14, 1975-2014
Table 26: Childhood Leukemia, Five-Year Relative Survival, Age 0-19, 1975-2014
Table 27: Subtypes of Non-Hodgkin Lymphoma, by Type
Table 28: Non-Hodgkin Lymphoma, Stages and Modifying Features
Table 29: Drugs Approved for Non-Hodgkin Lymphoma
Table 30: Monoclonal Antibodies Approved for Non-Hodgkin Lymphoma
Table 31: Subtypes of Hodgkin Lymphoma, by Type
Table 32: Hodgkin Lymphoma, Stages and Modifying Features
Table 33: Therapies Approved for Classical Hodgkin Lymphoma
Table 34: Hodgkin Lymphoma, Annual Incidence Rates, 2011-2015
Table 35: Global Market for Lymphoma Therapeutics, by Region, Through 2023
Table 36: Effect of Treatment on Multiple Myeloma
Table 37: Therapies Approved for Multiple Myeloma
Table 38: Chemotherapy Drugs for Multiple Myeloma
Table 39: Effect of Treatment on Multiple Myeloma
Table 40: Global Market for Multiple Myeloma Therapeutics, by Region, Through 2023
Table 41: Drug Approved for Hairy Cell Leukemia
Table 42: Global Market for Blood Cancer Therapeutics, by Region, Through 2023
Table 43: North American Estimated Incidence of Blood Cancer, by Country, 2018
Table 44: North American Market for Blood Cancer Therapeutics, by Disease Type, Through 2023
Table 45: North American Market for Leukemia Therapeutics, by Subtype, 2017-2023
Table 46: North American Market for Blood Cancer Therapeutics, by Country, Through 2023
Table 47: European Estimated Incidence of Blood Cancer, by Country, 2018
Table 48: European Market for Blood Cancer Therapeutics, by Disease Type, Through 2023
Table 49: European Market for Leukemia Therapeutics, by Subtype, 2017-2023
Table 50: European Market for Blood Cancer Therapeutics, by Country, Through 2023
Table 51: Asia-Pacific Estimated Incidence of Blood Cancer, by Country, 2018
Table 52: Asia-Pacific Market for Blood Cancer Therapeutics, by Disease Type, Through 2023
Table 53: Asia-Pacific Market for Leukemia Therapeutics, by Subtype, Through 2023
Table 54: Asia-Pacific Market for Blood Cancer Therapeutics, by Country, Through 2023
Table 55: Rest of the World Estimated Incidence of Blood Cancer, by Country, 2018
Table 56: Rest of the World Market for Blood Cancer Therapeutics, by Disease Type, Through 2023
Table 57: Rest of the World Market for Leukemia Therapeutics, by Subtype, Through 2023
Table 58: Pipeline: Phase I, 2018
Table 59: Pipeline, Phase II, 2018
Table 60: Pipeline, Phase III, 2018
Table 61: Potential Drugs, Indication and Estimated Filing, 2018
Table 62: Patent Expiration of Blood Cancer Drugs
Table 63: Key Developments, 2016-2018
Table 64: AbbVie Inc.: Marketed Products
Table 65: AbbVie Inc.: Net Revenue, 2015-2017
Table 66: Amgen Inc.: Marketed Products
Table 67: AstraZeneca plc: Marketed Products
Table 68: AstraZeneca plc: Net Revenue, 2014-2017
Table 69: Boehringer Ingelheim GmbH: Net Revenue, 2015-2017
Table 70: Bristol-Myers Squibb Co.: Marketed Products
Table 71: Bristol-Myers Squibb Co.: Net Revenue, 2014-2016
Table 72: Celgene Corp.: Marketed Products
Table 73: Celgene Corp.: Net Revenue, 2015-2016
Table 74: Gilead Sciences Inc.: Net Revenue, 2014-2016
Table 75: GlaxoSmithKline plc: Net Revenue, 2014-2016
Table 76: F. Hoffmann-La Roche Ltd.: Marketed Products
Table 77: F. Hoffmann-La Roche Ltd.: Net Revenue, 2015-2017
Table 78: Johnson & Johnson Inc.: Net Revenue, 2014-2016
Table 79: Merck & Co., Inc.: Marketed Products
Table 80: Merck & Co., Inc.: Net Revenue, 2014-2016
Table 81: Novartis AG: Marketed Products
Table 82: Novartis AG: Net Revenue, 2014-2016
Table 83: Pfizer Inc.: Marketed Products by Indication
Table 84: Pfizer Inc.: Net Revenue, 2015-2017
Table 85: Teva Pharmaceutical Industries Ltd.: Marketed Products
Table 86: Teva Pharmaceutical Industries Ltd.: Net Revenue, 2015-2017
Table 87: Acronyms Used in This Blood Cancer Therapeutics Report
Table 88: Glossary of Terms Used in This Blood Cancer Therapeutics Report
Summary Table: Global Market for Blood Cancer Therapeutics, by Disease Type, Through 2023
Table 1: Type of Blood Cancers (Hematological Cancer)
Table 2: Milestones in the History of Leukemia
Table 3: Product Approvals, 2016-2018
Table 4: Classification of Leukemia
Table 5: Types of Leukemia, Key Features, Occurrence
Table 6: Diagnostic Examination for Leukemia
Table 7: PCR Tests
Table 8: Additional Tests
Table 9: Treatments for Leukemia
Table 10: Newer Classes of Drugs
Table 11: Types of Stem Cell Transplantation
Table 12: Types of Targeted Therapies
Table 13: Types of Radiation Therapies
Table 14: Global Market for Leukemia Therapeutics, by Subtype, Through 2023
Table 15: Global Market for Leukemia Therapeutics, by Region, Through 2023
Table 16: Acute Lymphoblastic Leukemia (ALL) Treatment
Table 17: Therapies Approved for Acute Lymphoblastic Leukemia (ALL)
Table 18: Global Market for Acute Lymphocytic Leukemia (ALL) Therapeutics, by Region, Through 2023
Table 19: Therapies Approved for Acute Myeloid Leukemia
Table 20: Global Market for Acute Myeloid Leukemia Therapeutics, by Region, Through 2023
Table 21: Therapies Approved for Chronic Myeloid Leukemia
Table 22: Global Market for Chronic Myeloid Leukemia Therapeutics, by Region, Through 2023
Table 23: Therapies Approved for Chronic Lymphocytic Leukemia
Table 24: Global Market for Chronic Lymphocytic Leukemia Therapeutics, by Region, Through 2023
Table 25: Childhood Leukemia, Five-Year Relative Survival, Age 0-14, 1975-2014
Table 26: Childhood Leukemia, Five-Year Relative Survival, Age 0-19, 1975-2014
Table 27: Subtypes of Non-Hodgkin Lymphoma, by Type
Table 28: Non-Hodgkin Lymphoma, Stages and Modifying Features
Table 29: Drugs Approved for Non-Hodgkin Lymphoma
Table 30: Monoclonal Antibodies Approved for Non-Hodgkin Lymphoma
Table 31: Subtypes of Hodgkin Lymphoma, by Type
Table 32: Hodgkin Lymphoma, Stages and Modifying Features
Table 33: Therapies Approved for Classical Hodgkin Lymphoma
Table 34: Hodgkin Lymphoma, Annual Incidence Rates, 2011-2015
Table 35: Global Market for Lymphoma Therapeutics, by Region, Through 2023
Table 36: Effect of Treatment on Multiple Myeloma
Table 37: Therapies Approved for Multiple Myeloma
Table 38: Chemotherapy Drugs for Multiple Myeloma
Table 39: Effect of Treatment on Multiple Myeloma
Table 40: Global Market for Multiple Myeloma Therapeutics, by Region, Through 2023
Table 41: Drug Approved for Hairy Cell Leukemia
Table 42: Global Market for Blood Cancer Therapeutics, by Region, Through 2023
Table 43: North American Estimated Incidence of Blood Cancer, by Country, 2018
Table 44: North American Market for Blood Cancer Therapeutics, by Disease Type, Through 2023
Table 45: North American Market for Leukemia Therapeutics, by Subtype, 2017-2023
Table 46: North American Market for Blood Cancer Therapeutics, by Country, Through 2023
Table 47: European Estimated Incidence of Blood Cancer, by Country, 2018
Table 48: European Market for Blood Cancer Therapeutics, by Disease Type, Through 2023
Table 49: European Market for Leukemia Therapeutics, by Subtype, 2017-2023
Table 50: European Market for Blood Cancer Therapeutics, by Country, Through 2023
Table 51: Asia-Pacific Estimated Incidence of Blood Cancer, by Country, 2018
Table 52: Asia-Pacific Market for Blood Cancer Therapeutics, by Disease Type, Through 2023
Table 53: Asia-Pacific Market for Leukemia Therapeutics, by Subtype, Through 2023
Table 54: Asia-Pacific Market for Blood Cancer Therapeutics, by Country, Through 2023
Table 55: Rest of the World Estimated Incidence of Blood Cancer, by Country, 2018
Table 56: Rest of the World Market for Blood Cancer Therapeutics, by Disease Type, Through 2023
Table 57: Rest of the World Market for Leukemia Therapeutics, by Subtype, Through 2023
Table 58: Pipeline: Phase I, 2018
Table 59: Pipeline, Phase II, 2018
Table 60: Pipeline, Phase III, 2018
Table 61: Potential Drugs, Indication and Estimated Filing, 2018
Table 62: Patent Expiration of Blood Cancer Drugs
Table 63: Key Developments, 2016-2018
Table 64: AbbVie Inc.: Marketed Products
Table 65: AbbVie Inc.: Net Revenue, 2015-2017
Table 66: Amgen Inc.: Marketed Products
Table 67: AstraZeneca plc: Marketed Products
Table 68: AstraZeneca plc: Net Revenue, 2014-2017
Table 69: Boehringer Ingelheim GmbH: Net Revenue, 2015-2017
Table 70: Bristol-Myers Squibb Co.: Marketed Products
Table 71: Bristol-Myers Squibb Co.: Net Revenue, 2014-2016
Table 72: Celgene Corp.: Marketed Products
Table 73: Celgene Corp.: Net Revenue, 2015-2016
Table 74: Gilead Sciences Inc.: Net Revenue, 2014-2016
Table 75: GlaxoSmithKline plc: Net Revenue, 2014-2016
Table 76: F. Hoffmann-La Roche Ltd.: Marketed Products
Table 77: F. Hoffmann-La Roche Ltd.: Net Revenue, 2015-2017
Table 78: Johnson & Johnson Inc.: Net Revenue, 2014-2016
Table 79: Merck & Co., Inc.: Marketed Products
Table 80: Merck & Co., Inc.: Net Revenue, 2014-2016
Table 81: Novartis AG: Marketed Products
Table 82: Novartis AG: Net Revenue, 2014-2016
Table 83: Pfizer Inc.: Marketed Products by Indication
Table 84: Pfizer Inc.: Net Revenue, 2015-2017
Table 85: Teva Pharmaceutical Industries Ltd.: Marketed Products
Table 86: Teva Pharmaceutical Industries Ltd.: Net Revenue, 2015-2017
Table 87: Acronyms Used in This Blood Cancer Therapeutics Report
Table 88: Glossary of Terms Used in This Blood Cancer Therapeutics Report
LIST OF FIGURES
Summary Figure: Global Market for Blood Cancer Therapeutics, by Disease Type, 2017-2023
Figure 1: Percentage Share of Global Blood Cancer Prevalence, 2018
Figure 2: Percentage Share of Cancer Incidence in the U.S., by Top 10 Cancer Types, 2018
Figure 3: U.S. Leukemia Statistics, by Annual Rates (per 100,000 Population) and Number of New Cases (Total Cases), 1999-2016
Figure 4: Awareness Campaigns
Figure 5: Types of Leukemia, Key Features, Occurrence
Figure 6: Global Market for Leukemia Therapeutics, 2017-2023
Figure 7: Global Market for Leukemia Therapeutics, by Subtype, 2017-2023
Figure 8: Global Market Share for Leukemia Therapeutics, by Subtype, 2018
Figure 9: Global Market Share for Leukemia Therapeutics, by Subtype, 2023
Figure 10: Global Market for Leukemia Therapeutics, by Region, 2017-2023
Figure 11: Global Market for Acute Lymphocytic Leukemia (ALL) Therapeutics, 2017-2023
Figure 12: Global Market for Acute Lymphocytic Leukemia (ALL) Therapeutics, by Region, 2017-2023
Figure 13: Global Market for Acute Myeloid Leukemia Therapeutics, 2017-2023
Figure 14: Global Market for Acute Myeloid Leukemia Therapeutics, by Region, 2017-2023
Figure 15: Global Market for Chronic Myeloid Leukemia Therapeutics, 2017-2023
Figure 16: Global Market for Chronic Myeloid Leukemia Therapeutics, by Region, 2017-2023
Figure 17: Global Market for Chronic Lymphocytic Leukemia Therapeutics, 2017-2023
Figure 18: Global Market for Chronic Lymphocytic Leukemia Therapeutics, by Region, 2017-2023
Figure 19: Global Market for Lymphoma Therapeutics, 2017-2023
Figure 20: Global Market for Lymphoma Therapeutics, by Region, 2017-2023
Figure 21: Global Market for Multiple Myeloma Therapeutics, 2017-2023
Figure 22: Global Market for Multiple Myeloma Therapeutics, by Region, 2017-2023
Figure 23: Global Market for Blood Cancer Therapeutics, 2017-2023
Figure 24: Global Market for Blood Cancer Therapeutics, by Region, 2017-2023
Figure 25: Percentage Share of North American Leukemia (Estimated) Incidence, by Country, 2018
Figure 26: Estimated Leukemia Incidence in the United States, by Type, 2016-2018
Figure 27: Percentage Share of Estimated Blood Cancer Incidence in Canada, 2016
Figure 28: Percentage Share of North American Non-Hodgkin Lymphoma Estimated Incidence, by Country, 2018
Figure 29: Percentage Share of North American Hodgkin Lymphoma Estimated Incidence, by Country, 2018
Figure 30: North American Market for Blood Cancer Therapeutics, 2017-2023
Figure 31: North American Market for Blood Cancer Therapeutics, by Disease Type, 2017-2023
Figure 32: North American Market for Leukemia Therapeutics, by Subtype, 2017-2023
Figure 33: North American Market for Blood Cancer Therapeutics, by Country, 2017-2023
Figure 34: U.K. Top 20 Common Causes of Cancer Death, by Country, 2016
Figure 35: European Market for Blood Cancer Therapeutics, 2017-2023
Figure 36: European Market for Blood Cancer Therapeutics, by Disease Type, 2017-2023
Figure 37: European Market for Leukemia Therapeutics, by Subtype, 2017-2023
Figure 38: European Market for Blood Cancer Therapeutics, by Country, 2017-2023
Figure 39: Asia-Pacific Market for Blood Cancer Therapeutics, 2017-2023
Figure 40: Asia-Pacific Market for Blood Cancer Therapeutics, by Disease Type, 2017-2023
Figure 41: Asia-Pacific Market for Leukemia Therapeutics, by Subtype, 2017-2023
Figure 42: Asia-Pacific Market for Blood Cancer Therapeutics, by Country, 2017-2023
Figure 43: Rest of the World Market for Blood Cancer Therapeutics, 2017-2023
Figure 44: Rest of the World Market for Blood Cancer Therapeutics, by Disease Type, 2017-2023
Figure 45: Rest of the World Market for Leukemia Therapeutics, by Subtype, 2017-2023
Figure 46: Federal and Inter-provincial Approval System for Cancer Drugs in Canada
Figure 47: AbbVie Inc.: Revenue Share, by Country, 2017
Figure 48: Boehringer Ingelheim GmbH: Revenue Share, by Region, 2017
Figure 49: Boehringer Ingelheim GmbH: Revenue Share, by Business Segment, 2017
Figure 50: Boehringer Ingelheim GmbH: R&D Expenditures, 2015-2017
Figure 51: Bristol-Myers Squibb Co.: Revenue Share, by Country/Region, 2017
Figure 52: Gilead Sciences Inc.: Revenue Share, by Business Segment, 2016
Figure 53: Gilead Sciences Inc.: Revenue Share, by Country/Region, 2016
Figure 54: GlaxoSmithKline plc: Revenue Share, by Business Segment, 2016
Figure 55: GlaxoSmithKline plc: Revenue Share, by Region, 2016
Figure 56: F. Hoffmann-La Roche Ltd.: Revenue Share, by Segment, 2017
Figure 57: F. Hoffmann-La Roche Ltd.: Revenue Share, by Region, 2017
Figure 58: Johnson & Johnson Inc.: Revenue Share, by Business Segment, 2016
Figure 59: Johnson & Johnson Inc.: Revenue Share, by Country/Region, 2016
Figure 60: Merck & Co., Inc.: Revenue Share, by Business Segment, 2016
Figure 61: Merck & Co., Inc.: Revenue Share, by Country/Region, 2016
Figure 62: Novartis AG: Revenue Share, by Country/Region, 2016
Figure 63: Novartis AG: Revenue Share, by Business Segment, 2016
Figure 64: Pfizer Inc.: Revenue Share, by Country/Region, 2016
Figure 65: Pfizer Inc.: Revenue Share, by Business Segment, 2016
Figure 66: Teva Pharmaceutical Industries Ltd.: Revenue Share, by Region, 2017
Figure 67: Teva Pharmaceutical Industries Ltd.: Revenue Share, by Business Segment, 2016
Summary Figure: Global Market for Blood Cancer Therapeutics, by Disease Type, 2017-2023
Figure 1: Percentage Share of Global Blood Cancer Prevalence, 2018
Figure 2: Percentage Share of Cancer Incidence in the U.S., by Top 10 Cancer Types, 2018
Figure 3: U.S. Leukemia Statistics, by Annual Rates (per 100,000 Population) and Number of New Cases (Total Cases), 1999-2016
Figure 4: Awareness Campaigns
Figure 5: Types of Leukemia, Key Features, Occurrence
Figure 6: Global Market for Leukemia Therapeutics, 2017-2023
Figure 7: Global Market for Leukemia Therapeutics, by Subtype, 2017-2023
Figure 8: Global Market Share for Leukemia Therapeutics, by Subtype, 2018
Figure 9: Global Market Share for Leukemia Therapeutics, by Subtype, 2023
Figure 10: Global Market for Leukemia Therapeutics, by Region, 2017-2023
Figure 11: Global Market for Acute Lymphocytic Leukemia (ALL) Therapeutics, 2017-2023
Figure 12: Global Market for Acute Lymphocytic Leukemia (ALL) Therapeutics, by Region, 2017-2023
Figure 13: Global Market for Acute Myeloid Leukemia Therapeutics, 2017-2023
Figure 14: Global Market for Acute Myeloid Leukemia Therapeutics, by Region, 2017-2023
Figure 15: Global Market for Chronic Myeloid Leukemia Therapeutics, 2017-2023
Figure 16: Global Market for Chronic Myeloid Leukemia Therapeutics, by Region, 2017-2023
Figure 17: Global Market for Chronic Lymphocytic Leukemia Therapeutics, 2017-2023
Figure 18: Global Market for Chronic Lymphocytic Leukemia Therapeutics, by Region, 2017-2023
Figure 19: Global Market for Lymphoma Therapeutics, 2017-2023
Figure 20: Global Market for Lymphoma Therapeutics, by Region, 2017-2023
Figure 21: Global Market for Multiple Myeloma Therapeutics, 2017-2023
Figure 22: Global Market for Multiple Myeloma Therapeutics, by Region, 2017-2023
Figure 23: Global Market for Blood Cancer Therapeutics, 2017-2023
Figure 24: Global Market for Blood Cancer Therapeutics, by Region, 2017-2023
Figure 25: Percentage Share of North American Leukemia (Estimated) Incidence, by Country, 2018
Figure 26: Estimated Leukemia Incidence in the United States, by Type, 2016-2018
Figure 27: Percentage Share of Estimated Blood Cancer Incidence in Canada, 2016
Figure 28: Percentage Share of North American Non-Hodgkin Lymphoma Estimated Incidence, by Country, 2018
Figure 29: Percentage Share of North American Hodgkin Lymphoma Estimated Incidence, by Country, 2018
Figure 30: North American Market for Blood Cancer Therapeutics, 2017-2023
Figure 31: North American Market for Blood Cancer Therapeutics, by Disease Type, 2017-2023
Figure 32: North American Market for Leukemia Therapeutics, by Subtype, 2017-2023
Figure 33: North American Market for Blood Cancer Therapeutics, by Country, 2017-2023
Figure 34: U.K. Top 20 Common Causes of Cancer Death, by Country, 2016
Figure 35: European Market for Blood Cancer Therapeutics, 2017-2023
Figure 36: European Market for Blood Cancer Therapeutics, by Disease Type, 2017-2023
Figure 37: European Market for Leukemia Therapeutics, by Subtype, 2017-2023
Figure 38: European Market for Blood Cancer Therapeutics, by Country, 2017-2023
Figure 39: Asia-Pacific Market for Blood Cancer Therapeutics, 2017-2023
Figure 40: Asia-Pacific Market for Blood Cancer Therapeutics, by Disease Type, 2017-2023
Figure 41: Asia-Pacific Market for Leukemia Therapeutics, by Subtype, 2017-2023
Figure 42: Asia-Pacific Market for Blood Cancer Therapeutics, by Country, 2017-2023
Figure 43: Rest of the World Market for Blood Cancer Therapeutics, 2017-2023
Figure 44: Rest of the World Market for Blood Cancer Therapeutics, by Disease Type, 2017-2023
Figure 45: Rest of the World Market for Leukemia Therapeutics, by Subtype, 2017-2023
Figure 46: Federal and Inter-provincial Approval System for Cancer Drugs in Canada
Figure 47: AbbVie Inc.: Revenue Share, by Country, 2017
Figure 48: Boehringer Ingelheim GmbH: Revenue Share, by Region, 2017
Figure 49: Boehringer Ingelheim GmbH: Revenue Share, by Business Segment, 2017
Figure 50: Boehringer Ingelheim GmbH: R&D Expenditures, 2015-2017
Figure 51: Bristol-Myers Squibb Co.: Revenue Share, by Country/Region, 2017
Figure 52: Gilead Sciences Inc.: Revenue Share, by Business Segment, 2016
Figure 53: Gilead Sciences Inc.: Revenue Share, by Country/Region, 2016
Figure 54: GlaxoSmithKline plc: Revenue Share, by Business Segment, 2016
Figure 55: GlaxoSmithKline plc: Revenue Share, by Region, 2016
Figure 56: F. Hoffmann-La Roche Ltd.: Revenue Share, by Segment, 2017
Figure 57: F. Hoffmann-La Roche Ltd.: Revenue Share, by Region, 2017
Figure 58: Johnson & Johnson Inc.: Revenue Share, by Business Segment, 2016
Figure 59: Johnson & Johnson Inc.: Revenue Share, by Country/Region, 2016
Figure 60: Merck & Co., Inc.: Revenue Share, by Business Segment, 2016
Figure 61: Merck & Co., Inc.: Revenue Share, by Country/Region, 2016
Figure 62: Novartis AG: Revenue Share, by Country/Region, 2016
Figure 63: Novartis AG: Revenue Share, by Business Segment, 2016
Figure 64: Pfizer Inc.: Revenue Share, by Country/Region, 2016
Figure 65: Pfizer Inc.: Revenue Share, by Business Segment, 2016
Figure 66: Teva Pharmaceutical Industries Ltd.: Revenue Share, by Region, 2017
Figure 67: Teva Pharmaceutical Industries Ltd.: Revenue Share, by Business Segment, 2016
